Apexigen Raises $73 Million In Series B And Series C Financings-- Proceeds to Support Ongoing Phase 2 Clinical Trials of Immuno-oncology Therapeutic APX005M and the Discovery and Development of a Pipeline of Novel Therapies -- SAN CARLOS, Calif., August 8, 2018-- Apexigen, Inc., a clinical-stage biopharmaceutical company, today announced the successful completion of its Series B and Series C financings in which it raised a total of $73 million. The $15 million Series B financing was led by Decheng Capital and the recent $58 million Series C financing was led by 3E Bioventures Capital, Virtus Inspire Ventures, and SV Tech Ventures.